Sickle cell disease (SCD) patients are at risk of high mortality and premature death. Although their life expectancy has increased in countries where adequate support is routinely available, 1 some patients with SCD still have a poor quality of life and/or develop complications associated with an increased risk of chronic organ damage. [2] [3] [4] Bone marrow transplantation (BMT) for SCD was successfully developed in the middle of the 1980s 5 and remains the only curative approach available so far. Despite increasing expertise, haematopoietic stem cell transplantation (HSCT) remains a procedure that carries the risks of graft-versus-host disease (GVHD), impaired fertility and transplant-related mortality. Up to now, only a limited number of series of HSCT in SCD patients have been published, [6] [7] [8] and new transplantation approaches are currently being developed such as non-myeloablative conditioning [9] [10] [11] [12] or cord blood transplantation. 13 Although hydroxyurea (HU) treatment for SCD children and young adults gives overall encouraging results [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and reduces mortality in adults with frequent painful episodes, 24 we have pursued our HSCT programme for selected patients with a suitable family donor. We review here the outcome of 24 consecutive HSCT for SCD carried out in our unit (the Haemato-Oncology Unit of the Hoˆpital Universitaire des Enfants, Brussels) since 1988. The aim of this study is to assess retrospectively the results of the transplant according to the pre-transplant SCD complications, the pre-transplant management and the conditioning regimen. Starting 1994, symptomatic SCD patients were exposed to HU. Thus, it was also of interest to compare the outcome of grafted patients on the basis of prior HU exposure.
Patients, donors and methods
In all, 24 children with SCD have received a HSCT in our unit between 1988 and 2002 (23 SCA, 1SD Punjab ). Informed consent was obtained from the patients and/or their parents. All patients and transplant details were retrospectively collected from case notes.
Patients' clinical characteristics
All patients were transplanted because of the severity of the disease: 17 patients had been admitted to hospital for vasoocclusive crises (VOC) more than twice a year, six had had at least one episode of acute chest syndrome, five had had at least one stroke/seizure, four had alloimmunization secondary to blood transfusions. The countries of origin were the Democratic Republic of Congo (19 patients), Angola (one patient), Cameroon (one patient), Central African Republic (one patient), Nigeria (one patient) and Morocco (one patient). Age at the time of transplant ranged from 2.25 to 14.16 years (median 7.20 years). There were nine females and 15 males. Follow-up period ranges from 1 to 15 years (median 8.7 years).
The pre-HSCT neurological work-up included EEG, CNS imaging by either CT-SCAN or MRI and, since 2000, transcranial doppler echography (TCD). Five patients had a pre-HSCT history of seizures or strokes and five additional patients had abnormalities in their pre-HSCT neurological work-up defined as MRI/magnetic resonance angiography showing small vessel or large vessel stroke or as blood velocity in the median cerebral artery 4200 cm/s at TCD.
Pre-HSCT SCD management
Before HSCT, eight patients had received more than three blood transfusions and 13 patients had been treated with HU for a period of time ranging from 0.6 to 4 years (median 2.16 years). Hydryoxyurea (20-35 mg/kg/day) was given until the start of conditioning regimen.
Conditioning regimen
The conditioning regimen consisted of the standard combination of busulphan (14 mg/kg) and cyclophosphamide (200 mg/kg) (Bu14/Cy200) in the first six patients; Bu16/Cy200/antithymocyte globulins (ATGs) (Fresenius) 80 mg/kg in the nine next patients (since November 1991) and Bu16/Cy200/ATG (Merieux) 12-20 mg/kg in the last nine patients (since July 2000).
We divided the patients into three groups according to their pre-HSCT management and conditioning regimen. The clinical characteristics of the three groups are shown in Table 1 . Six patients received neither ATG during conditioning nor HU prior to HSCT (HUÀ, ATGÀ, group 1). Five patients received ATG in the conditioning regimen but no HU prior to HSCT (HUÀ, ATG þ , group 2). In all, 13 patients with ATG in the conditioning regimen received HU (HU þ , ATG þ , group 3).
Donors and HSC source
Donors were siblings aged 0.66-27 years (median 8.75 years) at the time of transplant. In nine cases, donors and receivers were matched for sex. All but one patient received HLA-genoidentical transplant; one patient received a one antigen mismatched transplant (1Ag MMBMT). The source of stem cells consisted of bone marrow for 23 patients and peripheral blood (PBSCT) for one patient.
GVHD prophylaxis
To prevent GVHD, all the patients received cyclosporin A (CsA, 5 mg/kg/day for 6 months and progressively reduced thereafter) together with a short course of methotrexate (MTX, 12 mg/m 2 /day1, 10 mg/m 2 /day 3 and 6). Acute GVHD was treated with steroids as first-line therapy. Chronic GVHD was treated with steroids and azathioprine.
Anticonvulsant prophylaxis
Following the observation of a high incidence of convulsive episodes post transplantation, 25 the last 10 patients received clonazepam as an anticonvulsant prophylaxis from -12 to þ 100 days post transplant. Two patients received the same prophylaxis but for a shorter period (8 and 50 days post transplant). In addition, special care was taken to maintain the platelet count above 50 000/ml, the blood pressure, the plasma CsA and magnesium levels inside the normal ranges.
Antimicrobial prophylaxis
Prophylaxis of infections consisted in gut decontamination, acyclovir as well as trimethoprim/sulphamethoxazol (after PMN recovery) and immunoglobulin infusions (every 3 weeks) for 6 months post transplantation. Broad-spectrum antibiotics were given in the event of fever (along with amphotericin if fever persisted or if there was a suggested fungal infection). All patients were nursed in air-filtered rooms with reverse barrier nursing. After immune reconstitution, active immunizations with pertussis, polio, diphtheria, tetanus, influenza, pneumococcus vaccines were carried out.
Chimerism studies
Chimerism studies were performed by at least one of the following methods: (1) cytogenetics when there was a sex discrepancy between donor and receiver, (2) residual HbS levels when the donor had a A/A Hb genotype and (3) studies of variable numbers of tandem repeats in DNA for the others.
Statistical analysis
The Mann-Whitney U-test was used to compare groups. All cited P-values are two-sided.
Results
Before HSCT, the severity of SCD was similar in the three groups except for the lower number of blood transfusions in group 3, probably as a result of chronic HU treatment that was proven to reduce the need of transfusion in children and adults 14, 15 (Table 1) . Group 3 patients had significant lower preconditioning absolute neutrophil count (ANC) than groups 1 and 2 (Po0.05), which again could result from chronic HU treatment. Mean age at HSCT is 7 years (range 1.8-14.2) in groups 1 and 2 and 7.4 years (3.8-12.3) in group 3.
Engraftment was observed in 21 patients, whereas three patients never presented any sign of engraftment. After engraftment, we observed one early rejection (31 days) rescued by a donor leucocyte infusion, one late rejection (14 months) and one stable mixed chimerism.
One patient unexplainably died at home 6 years post transplant at the age of 16 years. He had a complete donor chimerism with a normal level of Hb and full immune reconstitution, had recovered from cGVHD and was without any medical treatment at the time of his death. Unfortunately, post-mortem examination and analysis could not reveal the cause of his death. Overall, 23 of the 24 SCD children who received HSCT in our unit are currently alive.
We observed grade III acute GVHD in three patients, grade II aGVHD in three patients and chronic nonextensive GVHD in seven patients (two de novo). cGVHD required 2 years of immunosuppressive therapy in four children, which has now been stopped in all but one patient.
Seizures occurred in eight patients from 10 days to 13 months post HSCT: three early seizures and five late seizures. After 1994 (introduction of prophylactic clonazepam), no seizure complicated the early post HSCT period (o100 days post HSCT) but late seizures occurred (6-13 months) while still on CsA. All the three patients with early seizures had CNS infarcts on brain imaging prior to HSCT. Among the five patients with late seizures, one had an abnormal MRI and EEG, one a pre-HSCT seizure history and two an abnormal pre-HSCT TCD.
Fever occurred in all patients in the early post HSCT period (within 100 day post HSCT). In 11 of these febrile episodes, we documented an infection (six Gram-positive sepsis, two Escherichia coli urinary tract infections, three enteritis, one CMV reactivation with interstitial lung disease).
Seven girls and four boys are assessable for gonadal function. All but one of the girls have ovarian insufficiency with very high levels of circulating gonadotrophins. The boys have moderately elevated circulating gonadotrophins and moderately low levels of circulating testosterone. Their final height is in the normal range. Group 1 -patients received neither HU prior to HSCT nor ATG during the conditioning (HUÀ, ATGÀ). Group 2 -patients have not been treated with HU prior to HSCT but received ATG during the conditioning (HUÀ, ATG +). Group 3 -patients received both HU prior to HSCT and ATG during the conditioning (HU+, ATG+).
As seen in Table 2 , we assessed the outcome of HSCT according to pre-HSCT management with groups 1-3 being described above.
In group 1 (HUÀ, ATGÀ), we observed one unexplainable late death, one absent engraftment, one late rejection 14 months post HSCT when CsA had been discontinued for 2 months and one mixed stable chimerism 15 months post HSCT. In group 2 (HUÀ, ATG þ ), we observed the absence of engraftment in two patients and one early rejection 31 days post HSCT that was controlled by steroids and donor lymphocytes infusion (DLI). In group 3 (HU þ , ATG þ ), we observed no cases of either absent engraftment, mixed stable chimerism or late rejection.
With respect to the complications of HSCT according to pre-HSCT management, group 1 included one de novo cGVHD and one early seizure; group 2, one aGVHD followed by cGVHD and one de novo cGVHD; group 3, five aGVHD, four cGVHD cases were observed and five late seizures were observed.
There is a statistically significant association between engraftment and (1) HSCT performed after 1995 and (2) HU treatment prior to HSCT. With respect to GVHD occurrence, donors' age is the only statistically significant associated factor: a lower cGVHD occurrence is seen with young donors (o10 years old). ANC before conditioning were different (Po0.05) between groups 1 and 2 and group 3. (Table 1) .
Overall, 20 of 24 transplanted children have had stable engraftment and have remained free of SCD-related symptoms after HSCT. Of these, 19 of them are alive and cured of SCD with normal activity and attendance to school or work. Of these, three patients have required immunosuppression for chronic GVHD (nonextensive) for 2 years post HSCT.
Discussion and conclusion
Chronic treatment with HU reduces the frequency/severity of VOC, ACS and strokes in some SCD patients 14, 16, 19 and has recently been shown to reduce mortality in adult patients. 24 Along with the benefits of HU treatment, accurate data on the outcome of HSCT is necessary to enable patients with an HLA-identical sib and their caregivers to decide whether to perform HSCT or not. 26 We therefore analysed the data of 24 allogeneic HSCT performed in SCD children in our institution.
The overall survival is 96% and 19 of the 23 survivors remain free of SCD-related symptoms and should be regarded as cured from SCD after a median follow-up of 8.7 years. Of interest, our results clearly have improved with time since neither death nor graft rejection occurred since 1995.
Given the relatively small number and heterogeneity of the patients, the factors that influence the results are probably multiple. Nevertheless, we do not think that the improvement of the results derives from patient selection bias as both SCD-related complications and median age at HSCT are similar between the transplantation periods considered (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) . Our criteria for eligibility for transplantation have been unchanged since 1988: (1) recurrent ACS and/or (2) stroke and/or (3) more than 2 VOC/year and/or (4) alloimmunization and/or (5) osteonecrosis, with a suitable family donor. Retrospectively all our patients but one fulfilled the Paediatric Haematology Forum Criteria. 27 Patients free of SCD-related symptoms while on HU but fulfilling inclusion criteria before starting HU remain eligible for HSCT in our institution. This attitude is based on the facts that the very long-term benefits and hazards of HU are unknown, that transplantation gives better results in younger patients and that the increasing age of donors is associated with an increase in GVHD occurrence.
The conditioning regimen has also changed over time but in our single centre experience, the increase of busulphan dose and the introduction of immunotherapy have not improved the results (group 1 compared to group 2). This contrasts with the experience of the French Group, which did not experience graft rejection after conditioning with ATG. 6 The improvement of our results coincides with the start of chronic HU treatment of SCD. This observation could be accounted for by the myelosuppressive effect of HU as attested by lower ANC before the start of conditioning. It is well known that patients with chronic haemolytic anaemia such as SCD have myeloid and erythroid hyperplasia, which could in turn hinder engraftment. In thalassaemia, the results of HSCT after conventional conditioning in class 3 patients and the results of second HSCT after graft failure are poor, whereas preconditioning with cytoreductive-immunosuppressive drugs including HU seems to improve engraftment rate. 28 The need for an optimal control of medullary hypercellularity is also illustrated by the disappointing results of the nonmyeloablative conditioning protocols in SCD patients, suggesting that it remains of importance to 'create space in the marrow' for stable engraftment to take place in this kind of patient.
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In conclusion, we provide here a review of our single centre experience of HSCT for SCD in 24 children.
Furthermore, our data are the first to suggest a possible positive impact of chronic HU treatment prior to HSCT for SCD on stable engraftment and persistence of full donor chimerism. These preliminary results should be confirmed using a larger cohort of patients. Finally, HSCT has the advantage of a clear improvement in the quality of life despite the occurrence of chronic GVHD that was not, in our experience, debilitating as immunosuppression could be stopped after 2 years in all patients. As a whole, these results constitute an important element for consideration when patients, parents and careproviders need to make an informed choice between conservative treatment and HSCT in patients with a suitable family donor.
